Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atypical cellular disorders.

Kenneth L McClain1, Yasodha Natkunam, Steven H Swerdlow

  • 1Texas Children's Cancer Center/Hematology Service, Baylor College of Medicine, Houston, TX 77030, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report.

Leukemia·2026
Same author

Utility of ultrasensitive, US Food and Drug Administration-approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas.

American journal of clinical pathology·2026
Same author

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Blood advances·2026
Same author

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Blood advances·2026
Same author

TP53 genetic alterations are highly recurrent in Epstein-Barr virus-negative aggressive NK-cell leukemia: insights from an institutional experience and comprehensive literature review.

American journal of clinical pathology·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

This review compares Langerhans cell histiocytosis (LCH), Rosai-Dorfman disease (SHML), and Castleman's disease (CD), highlighting their distinct cellular origins, clinical presentations, and diagnostic criteria. Further clinical trials are needed for SHML and CD.

Area of Science:

  • Immunologic diseases
  • Atypical cellular disorders
  • Histiocytic and dendritic cell neoplasms

Background:

  • Immunologic diseases can involve profound loss or dysfunction of specific cell populations.
  • Atypical cellular disorders, including LCH, SHML, and CD, share similarities such as abnormal lymphocyte, macrophage, or dendritic cell proliferation leading to lymphadenopathy, rashes, bone lesions, and organ infiltration.

Purpose of the Study:

  • To elucidate the similarities and differences between Langerhans cell histiocytosis (LCH), sinus histiocytosis with massive lymphadenopathy (SHML) or Rosai-Dorfman disease, and Castleman's disease (CD).
  • To review the current understanding of LCH, SHML, and CD, including their pathogenesis, clinical features, diagnosis, and treatment.

Main Methods:

  • Review of existing literature and clinical trial data for LCH, SHML, and CD.

Related Experiment Videos

  • Examination of LCH pathogenesis, focusing on the debate between malignant clonal disorder versus inflammatory response.
  • Analysis of diagnostic features and treatment approaches for SHML and CD, including specific subtypes.

    • Main Results:

    • LCH: Debates persist regarding its etiology (clonal malignancy vs. inflammatory response), with evidence for clonality and loss of heterozygosity (LOH). Risk stratification and early treatment response are key prognostic factors.
    • SHML: Typically presents as painless cervical lymphadenopathy with potential extranodal involvement. Diagnosis involves identifying lymphocytes within macrophages. Etiology may involve HHV-6 and apoptosis defects. Treatment varies, with spontaneous regression possible.
    • CD: Four types exist, with localized forms often cured by surgery. Multicentric CD, particularly the plasmablastic type, is associated with HIV and HHV-8 infection, often presenting with constitutional symptoms and requiring systemic therapy.

    Conclusions:

    • LCH, SHML, and CD are distinct atypical cellular disorders with overlapping but unique clinical and pathological features.
    • While LCH has benefited from organized clinical trials, SHML and CD require further investigation and clinical trials to optimize therapeutic strategies.
    • Registration of patients on existing LCH trials is encouraged, and future research should focus on the etiology and treatment of SHML and CD.